Cover Image

Update breast cancer 2021 part 5 - Advanced breast cancer = Update Mammakarzinom 2021 Teil 5 - fortgeschrittenes Mammakarzinom

<p>Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase in...

Full description

Saved in:
Bibliographic Details
Main Authors: Lüftner, Diana (Author) , Schütz, Florian (Author) , Stickeler, Elmar (Author) , Fasching, Peter A. (Author) , Janni, Wolfgang (Author) , Kolberg-Liedtke, Cornelia (Author) , Kolberg, Hans-Christian (Author) , Thomssen, Christoph (Author) , Müller, Volkmar (Author) , Fehm, Tanja (Author) , Belleville, Erik (Author) , Bader, Simon (Author) , Untch, Michael (Author) , Welslau, Manfred (Author) , Thill, Marc (Author) , Tesch, Hans (Author) , Ditsch, Nina (Author) , Lux, Michael P. (Author) , Wöckel, Achim (Author) , Aktas, Bahriye (Author) , Schneeweiss, Andreas (Author) , Würstlein, Rachel (Author) , Hartkopf, Andreas D. (Author)
Format: Article (Journal)
Language:English
Published: [2022]
In: Geburtshilfe und Frauenheilkunde
Year: 2022, Volume: 82, Issue: 2, Pages: 215-225
ISSN:1438-8804
DOI:10.1055/a-1724-9569
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1724-9569
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1724-9569
Get full text
Author Notes:Diana Lüftner, Florian Schütz, Elmar Stickeler, Peter A. Fasching, Wolfgang Janni, Cornelia Kolberg-Liedtke, Hans-Christian Kolberg, Christoph Thomssen, Volkmar Müller, Tanja N. Fehm, Erik Belleville, Simon Bader, Michael Untch, Manfred Welslau, Marc Thill, Hans Tesch, Nina Ditsch, Michael P. Lux, Achim Wöckel, Bahriye Aktas, Andreas Schneeweiss, Rachel Würstlein, Andreas D. Hartkopf
Description
Summary:<p>Despite the COVID 19 pandemic and mostly virtual congresses, innovation in the treatment of breast cancer patients continues at an unabated pace. This review summarises the current developments. Initial overall survival data for CDK4/6 inhibitor treatment in combination with an aromatase inhibitor as the first advanced line of therapy in treatment-naive postmenopausal patients have been published. Similarly, a trial comparing trastuzumab-deruxtecan versus trastuzumab-emtansine revealed a clear benefit regarding progression-free survival. Understanding of biomarkers making checkpoint inhibitor therapy particularly effective is increasing, and new compounds such as oral selective estrogen receptor destabilisers (SERDs) are entering clinical development and completing the first phase III trials.</p>
Item Description:Gesehen am 16.11.2022
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1724-9569

Similar Items